Post-earnings recap
Reported
Wed, Jul 24, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
Boston Scientific's earnings report showed a slight miss on EPS, which may indicate some pressure on profitability. The stock reacted minimally, down just 0.02%, suggesting that investors may have anticipated the results. Management's focus on innovation and long-term growth could provide a positive outlook, but the lack of revenue data leaves some uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.39 | N/A | -0.19% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed a cautious optimism about future growth despite current market challenges. They emphasized their commitment to innovation.
Management highlighted ongoing investments in innovation and product development.
They noted challenges in certain markets but remain focused on long-term growth.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—